CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 315 enrolled
Drug / intervention
Oral Polio Vaccine (OPV)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02961595
NCT02961595Phase 1Completed
CompareCT.gov

Live Enterovirus Vaccine and Type 1 Diabetes

Tampere University·interventional·Posted Nov 11, 2016·Updated Aug 13, 2024

In Brief

A Phase 1 clinical trial evaluating Oral Polio Vaccine (OPV) for Enterovirus Infection and 2 related conditions. Completed, enrolled 315 participants.

Detailed Summary

Enterovirus infections may either increase or decrease the risk of type 1 diabetes depending on the age of infection and the type of enterovirus in question. This study evaluated whether early serial exposures to three replication-competent enterovirus strains (live poliovirus vaccine, OPV) can influence the immunity to other enteroviruses and the possible initiation of autoantibodies e.g. islet autoimmunity in young genetically predisposed children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnterovirus Infection, Type 1 Diabetes, Prediabetic State
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 11, 2016
Enrollment StartOct 1, 1999
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 17.1 yearsPosted 9.6 years ago

Interventions

Oral Polio Vaccine (OPV)biological

Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).